ClinicalTrials.gov
ClinicalTrials.gov Menu

Using Ex-vivo Normothermic Machine Perfusion With the Organox Metra™ Device to Store Human Livers for Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02478151
Recruitment Status : Enrolling by invitation
First Posted : June 23, 2015
Last Update Posted : October 11, 2018
Sponsor:
Information provided by (Responsible Party):
University Health Network, Toronto

Brief Summary:
This trial will examine the safety and feasibility of using the OrganOx Metra device to transport and store donor livers under normothermic conditions prior to transplantation. Participants will be followed for 3 months following transplantation and their outcomes recorded.

Condition or disease Intervention/treatment Phase
End-stage Liver Disease Device: OrganOx Metra Phase 1

Detailed Description:
Liver transplantation is a life-saving procedure but its success has been limited by a shortage of suitable donor organs. Much emphasis is now placed on optimising the condition of those organs that are available, to enable more higher risk organs to be transplanted safely. An effective means of pre-transplant viability assessment would not only allow greater use of higher risk donors but also minimise the risk of primary non-function by identifying and excluding non-viable organs before subjecting a patient to the risk of surgery. Organ storage under normothermic perfusion conditions enables organ function to be evaluated prior to transplantation and further has been shown to prevent organ injury which is sustained during standard cold storage. This trial will examine the safety and feasibility of using the OrganOx Metra device to transport and store donor livers under normothermic conditions prior to transplantation. This study will evaluate liver function post-transplantation using standard clinical parameters. Participants will be followed for 3 months following transplantation and their outcomes recorded. Participants will undergo no other study procedures. Feasibility will be measured using the ratio of actual / eligible candidate donors recruited to the study and will also encompass logistical issues with respect to transportation, and ease of use. Safety will be assessed by rates of device failures resulting in organ discard, primary graft non-function, re-transplantation, and recipient death.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A Single Centre Study of the Feasibility and Safety of Using Ex-vivo Normothermic Machine Perfusion With the Organox Metra™ Device to Store Human Livers for Transplantation
Actual Study Start Date : July 2015
Estimated Primary Completion Date : December 2019
Estimated Study Completion Date : April 2020

Arm Intervention/treatment
Experimental: OrganOx Metra
OrganOx Metra Device
Device: OrganOx Metra
Normothermic machine perfusion (NMP) Metra device




Primary Outcome Measures :
  1. Rates of primary graft non-function [ Time Frame: 3 months ]
  2. Rates of re-transplantation [ Time Frame: 3 months ]
  3. Rates of recipient death [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Rate of device failures resulting in organ discard [ Time Frame: 3 months ]
  2. Recruitment rates to the study [ Time Frame: 3 months ]
    Measured by the ratio of actual / eligible candidate donors recruited to the study

  3. Ischemia- reperfusion injury associated with organ storage [ Time Frame: 7 days ]
    Assessed by a post-perfusion biopsy

  4. Ischemia- reperfusion injury associated with organ storage [ Time Frame: 7 days ]
    Assessed by measuring the peak serum aspartate transaminase level (AST) within 7 days post-transplant

  5. The function of liver grafts stored with the Metra™ device [ Time Frame: 3 months ]
    Measured by bilirubin, alkaline phosphatase, AST and INR levels at days 1-7 post-transplant. The measure is a composite.

  6. The function of liver grafts stored with the Metra™ device [ Time Frame: 3 months ]
    Measured by bilirubin, alkaline phosphatase, AST and INR levels at day 30 post-transplant. The measure is a composite.

  7. The function of liver grafts stored with the Metra™ device [ Time Frame: 3 months ]
    Measured by bilirubin, alkaline phosphatase, AST and INR levels at month 3 post-transplant. The measure is a composite.

  8. The function of liver grafts stored with the Metra™ device [ Time Frame: 3 months ]
    Measured by Lactate at days 1-3 post-transplant. The measure is a composite.

  9. The ability of perfusion parameters to predict clinical outcomes following transplantation [ Time Frame: 3 months ]
    Perfusion flows and pressures will be studied to determine their correlation with graft injury and function. The measure is a composite.

  10. The ability of perfusion parameters to predict clinical outcomes following transplantation [ Time Frame: 3 months ]
    Perfusate blood gas parameters will be studied to determine their correlation with graft injury and function. The measure is a composite.

  11. The ability of perfusion parameters to predict clinical outcomes following transplantation [ Time Frame: 3 months ]
    Bile production will be studied to determine their correlation with graft injury and function



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adult patients (18 years or more)
  • Active on the waiting list for liver transplantation
  • Able to give informed consent

Exclusion Criteria:

  • Age less than 18 years
  • Acute/fulminant liver failure
  • Transplantation of more than one organ (e.g. liver and kidney)
  • Refusal of informed consent
  • Unable to give informed consent
  • Re-transplantation Diagnosis of Hepatopulmonary Syndrome

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02478151


Locations
Canada, Ontario
Toronto General Hospital
Toronto, Ontario, Canada, M5G 2N2
Sponsors and Collaborators
University Health Network, Toronto
Investigators
Principal Investigator: David R Grant, MD University Health Network, Toronto

Responsible Party: University Health Network, Toronto
ClinicalTrials.gov Identifier: NCT02478151     History of Changes
Other Study ID Numbers: 14-8132-B
First Posted: June 23, 2015    Key Record Dates
Last Update Posted: October 11, 2018
Last Verified: October 2018

Keywords provided by University Health Network, Toronto:
Deceased donor liver transplant
Normothermic machine perfusion

Additional relevant MeSH terms:
Liver Diseases
End Stage Liver Disease
Digestive System Diseases
Liver Failure
Hepatic Insufficiency